









Markets
/
Stocks
/
nasdaq-ebs
/

Emergent BioSolutions Inc

EBS

7.930USD

-0.140-1.73%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

286.75MMarket Cap

8.07P/E TTM



Emergent BioSolutions Inc

7.930

-0.140-1.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Emergent BioSolutions Inc

Currency: USD Updated: 2026-03-27

Key Insights

Emergent BioSolutions Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Emergent BioSolutions Inc's Score

Industry at a Glance

Industry Ranking

75 / 157

Overall Ranking

193 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Emergent BioSolutions Inc Highlights

StrengthsRisks

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 8.07, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.86M shares, increasing 0.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.55M shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

12.000

Target Price

+48.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Emergent BioSolutions Inc is 7.55, ranking 101 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 148.70M, representing a year-over-year decrease of 23.63%, while its net profit experienced a year-over-year decrease of 74.44%.

Score

Industry at a Glance

Previous score

7.55

Change



Financials

6.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.07

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Emergent BioSolutions Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Emergent BioSolutions Inc is 5.86, ranking 135 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 8.07, which is 39.97% below the recent high of 11.29 and 147.82% above the recent low of -3.86.

Score

Industry at a Glance

Previous score

5.86

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Emergent BioSolutions Inc is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 13.50, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

12.000

Target Price

+48.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Emergent BioSolutions Inc

EBS

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Emergent BioSolutions Inc is 6.47, ranking 109 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.80 and the support level at 7.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.70

Change

-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.176

Neutral

RSI(14)

32.968

Neutral

STOCH(KDJ)(9,3,3)

27.559

Sell

ATR(14)

0.318

High Vlolatility

CCI(14)

-115.479

Sell

Williams %R

89.189

Oversold

TRIX(12,20)

-1.064

Sell

StochRSI(14)

24.038

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

8.056

Sell

MA10

8.096

Sell

MA20

8.274

Sell

MA50

9.992

Sell

MA100

10.771

Sell

MA200

9.416

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Emergent BioSolutions Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 83.14%, representing a quarter-over-quarter decrease of 2.05%. The largest institutional shareholder is The Vanguard, holding a total of 3.55M shares, representing 6.86% of shares outstanding, with 15.93% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

3.90M

+1.97%

The Vanguard Group, Inc.

Star Investors

3.54M

-1.21%

State Street Investment Management (US)

2.45M

+40.50%

American Century Investment Management, Inc.

2.38M

+3.94%

Dimensional Fund Advisors, L.P.

2.14M

+15.75%

Charles Schwab Investment Management, Inc.

1.38M

+25.02%

Palisade Capital Management, LLC

1.43M

+29.67%

Geode Capital Management, L.L.C.

1.28M

-0.02%

Oak Hill Advisors, L.P.

1.11M

Acadian Asset Management LLC

1.18M

+20.84%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Emergent BioSolutions Inc is 4.03, ranking 95 out of 157 in the Pharmaceuticals industry. The company's beta value is 2.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.